In Pursuit of Clinical Remission: Optimizing the Pharmacologic Management of Rheumatoid Arthritis
Vivian Bykerk, MD
Associate Attending Rheumatologist, Hospital for Special Surgery
Associate Professor of Medicine, Weill Cornell Medical College
Director, Inflammatory Arthritis Center of Excellence
New York, New York
Daniel E. Furst, MD
Professor of Rheumatology at the University of California in Los Angeles
Professor of Rheumatology at the University of Washington in Seattle Washington
Professor of Rheumatology at the University of Florence in Florence Italy.
Director of Research at Pacific Research Associates in Los Angeles, California
This enduring activity is focused on use of biologics and targeted therapies in the management of rheumatoid arthritis.
This activity is designed to meet the educational needs of primarily rheumatologists with a secondary audience of internists and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.
Upon completion of this activity, participants will be able to:
- Describe the role of inflammatory cytokines, both articularly and systemically, in the pathogenesis of rheumatoid arthritis
- Review the clinical trials data supporting the medical society pharmacologic recommendations for patients with moderate-to-severe rheumatoid arthritis
- Discuss the use of interleukin-6 inhibition as a treat-to-target strategy in patients with moderate-to-severe RA
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the treatment and management of patients with rheumatoid arthritis.
1.25 ANCC Contact Hour(s)
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.25 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Vivian Bykerk has received consulting fees from Amgen, fNIH, Pfizer, UCB, Scipher, and Sanofi Regeneron.
Dr. Daniel E Furst is on the speakers’ bureaus for CMC Connect McCann Health Company. He has received consulting fees from AbbVie, Actelion, Amgen, BMS, Cytori, Novartis, Pfizer, and
Roche/Genentech. Dr Furst has received grant/research support from AbbVie, Actelion, Amgen, BMS Corbus, NIH, and Novartis.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Cathy Herbert, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Melissa Johnson, Sr. Program Manager for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lectures, Drs. Bykerk and Furst may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.
Participants will receive their certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: February 25, 2019
EXPIRATION DATE: February 25, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.